Galderma Group AG Reports Robust Long‑Term Efficacy of Nemluvio in Atopic Dermatitis

October 8, 2026 – Swiss dermatology specialist Galderma Group AG announced the results of a post‑hoc analysis of the ARCADIA long‑term extension (LTE) study, focusing on the drug Nemluvio (nemolizumab). The data, released by the company on the day of the market’s closing, demonstrate sustained clinical benefits in patients aged 12 and older with atopic dermatitis.

Key Findings from the ARCADIA LTE Post‑hoc Analysis

  • Deep and lasting lesion response: The majority of patients exhibited clinically significant reduction in skin lesions by Week 12 of the LTE, a trend that persisted through the study’s final assessment point.
  • Improved itch control: Patients reported marked itch relief, with the proportion experiencing a ≥75 % improvement in itch severity scores exceeding 60 % at the study’s endpoint.
  • Safety profile: No new safety signals emerged; the incidence of adverse events remained consistent with the primary ARCADIA trial.

These results reinforce Nemluvio’s positioning as a first‑in‑class, anti‑IL‑31 monoclonal antibody for moderate‑to‑severe atopic dermatitis, potentially expanding its indication to a broader patient demographic.

Market Context

Galderma’s shares traded at CHF 162.60 on 6 October 2026, within a 52‑week range that has seen a high of CHF 188.25 (29 June 2026) and a low of CHF 134.70 (16 October 2025). The company’s market capitalization stands at CHF 37.63 billion, reflecting investor confidence in its dermatology pipeline despite a high price‑to‑earnings ratio of 78.21.

The Swiss Market Index (SMI) remained largely flat during the week, with minor gains that suggest a stable trading environment. This backdrop provides a measured setting for Galderma’s clinical advances to translate into shareholder value.

Strategic Implications

The LTE data support ongoing discussions with regulatory authorities regarding an expanded label for Nemluvio. A successful label extension could unlock additional revenue streams and reinforce Galderma’s leadership in targeted biologic therapies for skin disorders.

Furthermore, the sustained efficacy signals may enhance Galderma’s attractiveness in strategic partnership talks or potential acquisitions within the dermatology space, positioning the company for continued growth in a competitive market.

Outlook

  • Commercial launch: Anticipated in the next fiscal quarter, contingent on regulatory approval.
  • Pipeline expansion: Galderma continues to explore novel indications for Nemluvio, including pruritus associated with other chronic dermatoses.
  • Investor sentiment: The company’s robust clinical data and stable share performance are likely to attract long‑term investors focused on specialty therapeutics.

Galderma’s latest findings underscore its commitment to delivering durable, patient‑centered solutions while navigating a complex regulatory landscape. As the company moves forward, the market will keenly monitor how these clinical insights translate into commercial success and shareholder returns.